LYSSA
MCID: RBS001
MIFTS: 58

Rabies (LYSSA)

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Rabies

MalaCards integrated aliases for Rabies:

Name: Rabies 12 74 52 58 54 42 3 43 15 71 32
Lyssa 12 52

Characteristics:

Orphanet epidemiological data:

58
rabies
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11260
ICD9CM 34 071
MeSH 43 D011818
NCIt 49 C28182
SNOMED-CT 67 14168008
ICD10 32 A82 A82.9
MESH via Orphanet 44 D011818
ICD10 via Orphanet 33 A82.0 A82.1 A82.9
UMLS via Orphanet 72 C0034494
Orphanet 58 ORPHA770
UMLS 71 C0034494

Summaries for Rabies

MedlinePlus : 42 Rabies is a deadly animal disease caused by a virus. It can happen in wild animals, including raccoons, skunks, bats and foxes, or in dogs, cats or farm animals. People get it from the bite of an infected animal. In people, symptoms of rabies include fever, headache and fatigue, then confusion, hallucinations and paralysis. Once the symptoms begin, the disease is usually fatal. A series of shots can prevent rabies in people exposed to the virus. You need to get them right away. If an animal bites you, wash the wound well; then get medical care. To help prevent rabies Vaccinate your pet. Rabies vaccines are available for dogs, cats and farm animals Don't let pets roam Don't approach stray animals. Animals with rabies might be aggressive and vicious, or tired and weak Centers for Disease Control and Prevention

MalaCards based summary : Rabies, also known as lyssa, is related to noma and riedel's fibrosing thyroiditis, and has symptoms including fever and pruritus. An important gene associated with Rabies is PML (Promyelocytic Leukemia), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs chloroquine and Proguanil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and kidney, and related phenotypes are nausea and vomiting and depressivity

Disease Ontology : 12 A viral infectious disease that results in inflammation located in brain or located in spinal cord, has material basis in Rabies virus, which is transmitted by bite of an infected animal, or transmitted by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis.

CDC : 3 Rabies is a fatal but preventable viral disease. It can spread to people and pets if they are bitten or scratched by a rabid animal. In the United States, rabies is mostly found in wild animals like bats, raccoons, skunks, and foxes. However, in many other countries dogs still carry rabies, and most rabies deaths in people around the world are caused by dog bites. The rabies virus infects the central nervous system. If a person does not receive theappropriate medical care after a potential rabies exposure, the virus can cause disease in the brain, ultimately resulting in death. Rabies can be prevented by vaccinating pets, staying away from wildlife, and seeking medical care after potential exposures before symptoms start.

Wikipedia : 74 Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early... more...

Related Diseases for Rabies

Diseases related to Rabies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 noma 10.7 NGFR ALB
2 riedel's fibrosing thyroiditis 10.6 CD40LG ALB
3 cork-handlers' disease 10.6 CD40LG ALB
4 kunjin encephalitis 10.6 STAT2 CD40LG
5 fournier gangrene 10.6 CD40LG ALB
6 heterophyiasis 10.5 CD40LG ALB
7 non-secretory myeloma 10.5 CD40LG ALB
8 candidiasis 10.5 TLR3 STAT1 CD40LG
9 astrakhan spotted fever 10.5 CD40LG CCL5
10 plasma cell neoplasm 10.5 NCAM1 CD40LG ALB
11 blood protein disease 10.5 NCAM1 CD40LG ALB
12 meningovascular neurosyphilis 10.5 CD40LG ALB
13 lassa fever 10.5 IRF3 DDX58 CD40LG
14 west nile virus 10.5 TLR3 IRF3 DDX58
15 rectal disease 10.5 TLR3 CD40LG ALB
16 herpangina 10.5 TLR3 DDX58 CD40LG
17 splenic abscess 10.4 CD40LG ALB
18 salmonellosis 10.4 TLR3 STAT1 ALB
19 acrodermatitis 10.4 CXCL10 CD40LG ALB
20 commensal bacterial infectious disease 10.4 TLR3 CD40LG ALB
21 multifocal motor neuropathy 10.4 CXCL10 CD40LG
22 crimean-congo hemorrhagic fever 10.4 MX1 DDX58 CXCL10
23 babesiosis 10.4 HSPA4 CD40LG ALB
24 common cold 10.4 TLR3 CCL5 ALB
25 acalculous cholecystitis 10.4 CD40LG ALB
26 biliary atresia 10.4 TLR3 MX1 ALB
27 chickenpox 10.4 TLR3 STAT1 CD40LG ALB
28 granulomatous hepatitis 10.4 CD40LG ALB
29 japanese encephalitis 10.4 TLR3 CXCL10 CCL5
30 opportunistic mycosis 10.4 TLR3 STAT1 CD40LG ALB
31 splenic disease 10.4 HSPA4 CD40LG ALB
32 polyradiculoneuropathy 10.4 CD40LG CCL5 ALB
33 meningoencephalitis 10.4 CD40LG CCL5 ALB
34 spotted fever 10.4 CXCL10 CD40LG CCL5
35 hepatitis a 10.4 TLR3 CXCL10 ALB
36 bacterial pneumonia 10.4 TLR3 CD40LG ALB
37 viral meningitis 10.4 CXCL10 CD40LG CCL5
38 dengue disease 10.4 CD40LG CCL5 ALB
39 lymphatic system disease 10.4 NCAM1 CD40LG ALB
40 chikungunya 10.4 STAT1 DDX58 CCL5
41 cutaneous lupus erythematosus 10.4 MX1 IRF7 CD40LG
42 cryptosporidiosis 10.4 HSPA4 CXCL10 CD40LG
43 gastrointestinal tuberculosis 10.4 CD40LG ALB
44 pyelonephritis 10.4 CXCL10 CCL5 ALB
45 interstitial keratitis 10.4 HSPA4 CD40LG
46 secondary progressive multiple sclerosis 10.4 CXCL10 CD40LG ALB
47 hepatitis e 10.4 TLR3 DDX58 CD40LG ALB
48 chronic mucocutaneous candidiasis 10.4 TLR3 STAT2 STAT1 HSPA4
49 rubella 10.4 TLR3 DDX58 CD40LG
50 viral hepatitis 10.4 TLR3 MX1 CD40LG ALB

Graphical network of the top 20 diseases related to Rabies:



Diseases related to Rabies

Symptoms & Phenotypes for Rabies

Human phenotypes related to Rabies:

58 31 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 31 hallmark (90%) Very frequent (99-80%) HP:0002017
2 depressivity 58 31 hallmark (90%) Very frequent (99-80%) HP:0000716
3 hallucinations 58 31 hallmark (90%) Very frequent (99-80%) HP:0000738
4 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
5 attention deficit hyperactivity disorder 58 31 hallmark (90%) Very frequent (99-80%) HP:0007018
6 anxiety 58 31 hallmark (90%) Very frequent (99-80%) HP:0000739
7 anorexia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002039
8 migraine 58 31 hallmark (90%) Very frequent (99-80%) HP:0002076
9 paresthesia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003401
10 diarrhea 58 31 hallmark (90%) Very frequent (99-80%) HP:0002014
11 recurrent pharyngitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100776
12 insomnia 58 31 hallmark (90%) Very frequent (99-80%) HP:0100785
13 vocal cord paresis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001604
14 excessive salivation 58 31 hallmark (90%) Very frequent (99-80%) HP:0003781
15 cerebral palsy 58 31 frequent (33%) Frequent (79-30%) HP:0100021
16 seizures 58 31 occasional (7.5%) Occasional (29-5%) HP:0001250
17 sudden cardiac death 58 31 occasional (7.5%) Occasional (29-5%) HP:0001645
18 reduced consciousness/confusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0004372
19 behavioral abnormality 58 Very frequent (99-80%)

UMLS symptoms related to Rabies:


fever, pruritus

MGI Mouse Phenotypes related to Rabies:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 ALB CD40LG CXCL10 DDX58 DHX58 DYNLL1
2 hematopoietic system MP:0005397 10.1 CCL5 CD40LG CXCL10 DDX58 DHX58 DYNLL1
3 homeostasis/metabolism MP:0005376 10 ALB CD40LG CXCL10 DDX58 DHX58 DYNLL1
4 immune system MP:0005387 9.86 ALB CCL5 CD40LG CXCL10 DDX58 DHX58
5 mortality/aging MP:0010768 9.5 ALB CD40LG CXCL10 DDX58 DHX58 DYNLL1

Drugs & Therapeutics for Rabies

Drugs for Rabies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
2
Proguanil Approved Phase 4 500-92-5 4923
3
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
4
Atovaquone Approved Phase 4 95233-18-4 74989
5
Metronidazole Approved Phase 4 443-48-1 4173
6
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
7
Vancomycin Approved Phase 4 1404-90-6 441141 14969
8
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
9 Antibodies, Blocking Phase 4
10 Anti-Inflammatory Agents Phase 4
11 Anti-Inflammatory Agents, Non-Steroidal Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Atovaquone, proguanil drug combination Phase 4
14 Antirheumatic Agents Phase 4
15 Chloroquine diphosphate Phase 4 50-63-5
16 Anthelmintics Phase 4
17 Analgesics Phase 4
18 Antimetabolites Phase 4
19 Anti-Bacterial Agents Phase 4
20 Antibiotics, Antitubercular Phase 4
21 Antitubercular Agents Phase 4
22 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
23
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
24
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
25
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
26
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
27 Cathartics Phase 3
28 Gastrointestinal Agents Phase 3
29 Laxatives Phase 3
30 Rho(D) Immune Globulin Phase 3
31 gamma-Globulins Phase 3
32 Immunoglobulins, Intravenous Phase 3
33 Anti-Infective Agents Phase 3
34 Antiparasitic Agents Phase 3
35 Antiprotozoal Agents Phase 3
36 Antimalarials Phase 3
37 Pharmaceutical Solutions Phase 3
38 Renal Agents Phase 3
39 Anti-Infective Agents, Urinary Phase 3
40
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
41
Abacavir Approved, Investigational Phase 2 136470-78-5 65140 441300
42
Zidovudine Approved Phase 2 30516-87-1 35370
43
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
44
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
45
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
46 Immunoglobulin G Phase 1, Phase 2
47 Antineoplastic Agents, Immunological Phase 2
48 Cytochrome P-450 Enzyme Inhibitors Phase 2
49 Anti-Retroviral Agents Phase 2
50 Adjuvants, Immunologic Phase 2

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Unknown status NCT01173302 Phase 4
2 Diagnostic Immunization With Rabies Vaccine in Patients With Primary Immunodeficiency Disorders Unknown status NCT02490956 Phase 4
3 Immunogenicity and Safety of Purified Vero Cell Rabies Vaccine (PVRV, Verorab™) Administered for Rabies Post-exposure Treatment. Comparison of Essen-IM, Zagreb-IM, and Thai Red Cross (TRC)-ID Regimens in the Indian Population. Completed NCT00260351 Phase 4
4 Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level Completed NCT01827917 Phase 4
5 Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years Completed NCT02564471 Phase 4 Chloroquine;Atovaquone and Proguanil;Doxycycline
6 A Phase IV, Multi-center, Randomized, Open-label Study of PCECV (Rabipur®) Comparing the Immunogenicity and Safety of Two Different Simulated Post Exposure Schedules (Zagreb 2-1-1 Versus Essen Regimen 1-1-1-1-1) in Healthy Indian Subjects Completed NCT01365494 Phase 4
7 An Immunogenicity and Safety Study of Modified TRC-ID Regimen With A New Chromatographically Purified Vero Cell Rabies Vaccine(SPEEDA/TRCS SPEEDA) and Rabies Immunoglobulin Completed NCT01137045 Phase 4
8 Phase 4 Study of Speeda® Rabies Vaccine for Human Use Completed NCT01821911 Phase 4
9 Immunogenicity of a Two vs Three Dose, Intradermal (ID) vs Intramuscular (IM) Administration of a Licensed Rabies Vaccine for Pre-Exposure Vaccination Completed NCT02374814 Phase 4 Rabies vaccine;Placebo
10 A Phase IV, Open Label, Single-center Extension Study, to Evaluate the Long-term Persistence of Immune Responses After Post-exposure Prophylaxis With Purified Chicken-embryo Cell Rabies Vaccine in Chinese Children Completed NCT02991872 Phase 4
11 Safety of Rabivax-S in Individuals Receiving Pre-exposure Prophylaxis (PrEP) Completed NCT03741270 Phase 4
12 A Prospective Randomized Open Label Trial to Study the Systems Biology of Inactivated Rabies Vaccine in Healthy Adults With or Without Use of Broad Spectrum Antibiotics Recruiting NCT03557008 Phase 4 Metronidazole;Vancomycin;Neomycin Sulfate
13 Evaluation of Immune Response to Vaccines in Primary Immune Disorders Recruiting NCT00023504 Phase 4
14 Non-specific Effects of Rabies Vaccine on the Incidence of Common Infectious Disease Episodes: a Randomized Controlled Trial Enrolling by invitation NCT03656198 Phase 4 Sterile Water Injection
15 A Phase IV, Randomized, Open-label Study to Evaluate One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens (Zagreb 2-1-1 and Essen 1-1-1-1-1) in Chinese Children Withdrawn NCT03192371 Phase 4
16 A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Effectiveness of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) With Co-administration of Active Rabies Vaccine in Healthy Subjects Unknown status NCT02040090 Phase 2, Phase 3 Active rabies vaccine (US-FDA approved)
17 Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years. Completed NCT00345319 Phase 3
18 Safety and Immunogenicity of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans From 10-60 Years Old Completed NCT02288286 Phase 3
19 A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects. Completed NCT01662440 Phase 3
20 Phase 3, Randomized, Stratified, Open Label, Multicenter, Controlled Clinical Study to Evaluate Safety and Immunogenicity of a Rabies Vaccine Administered, With and Without Human Rabies Immunoglobulin, Using the New "4-sites, 1-week" Intradermal Regimen for Postexposure Prophylaxis Compared to the Currently Recommended "2-sites, TRC" Intradermal Regimen in Children and Adults Subjects. Completed NCT02177032 Phase 3
21 A Phase III, Single Center, Randomized, Open-label Study, Comparing PCECV Administered in the Abbreviated Zagreb Regimen (2-1-1) to the Conventional Essen Regimen (1-1-1-1-1) in Healthy Volunteers in China Completed NCT00825305 Phase 3
22 Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Post-exposure Use in Healthy Subjects in China Completed NCT01339312 Phase 3
23 Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine in Chinese Healthy People Aged 10-60 Years.: A Randomized, Blinded, Phase III Clinical Trial. Completed NCT03971370 Phase 3
24 A Single-centre, Randomized, Double-blind, Parallel Control, Phase 3 Study to Evaluate the Safety and Immunogenicity of a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Aged 10-60 Years Completed NCT02491541 Phase 3
25 Compare Immunogenicity, Safety and Long-term Booster Response After Primary Vaccination With 2 Intradermal Doses Versus 3 Intradermal Doses of PCEC Rabies Vaccine (Rabipur) in Healthy School Children in Thailand (5-8 Years of Age) Completed NCT01107275 Phase 3
26 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
27 A Phase IIIb, Randomized, Open-label Study Comparing Two Different Rabies Vaccine Post-exposure Schedules (Zagreb 2-1-1 and Rabipur® Essen 1-1-1-1-1) in Chinese Children and Older Adults Completed NCT01680016 Phase 3
28 Safety and Immunogenicity Study of GSK Biologicals' Plasmodium Falciparum Malaria Vaccine 257049 Administered to HIV Infected Infants and Children Completed NCT01148459 Phase 3
29 Simplifying the Rabies Pre-exposure Vaccination Completed NCT01388985 Phase 3
30 Verorab® Immunogenicity and Safety After a One-week, 4-site, Intradermal (ID) Post-exposure Prophylaxis Regimen (4-4-4-0-0) Followed by a One-visit, 4-site, ID Booster at Five Years Completed NCT01622062 Phase 3
31 Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 6 μg HA/Strain/0.5 ml) for Children and Adolescents Completed NCT02387294 Phase 3
32 Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Recruiting NCT02912845 Phase 3 KamRAB - HRIG
33 Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France Recruiting NCT03965962 Phase 3
34 Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and a Single Booster Dose of Purified Vero Rabies Vaccine - Serum Free Administered at 1 Year Post Primary Series in a Subset of Adults in Thailand Recruiting NCT04127786 Phase 3
35 A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults Who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis With Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately From a Japanese Encephalitis Vaccine. Active, not recruiting NCT02545517 Phase 3
36 Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscular Post-Exposure Prophylaxis Regimen at One Year Active, not recruiting NCT03700242 Phase 3
37 A Prospective, Randomized, Double-Blind Parallel-group, Non-inferiority Phase II/III Study of the Safety and Effectiveness of BPL HRIG With Co Administration of Active Rabies Vaccine in Healthy Subjects Active, not recruiting NCT03264157 Phase 2, Phase 3 HRIG;HyperRAB
38 A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined Active, not recruiting NCT03143218 Phase 3 SMC with SP+AQ;SMC placebo
39 One-visit Multi-site Pre-exposure Intradermal Rabies Vaccination: Dose Finding in Healthy Adults. Unknown status NCT02276625 Phase 2
40 Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. Completed NCT02559921 Phase 2
41 A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents Completed NCT00708084 Phase 2
42 Immunogenicity and Safety of a Purified Vero Rabies Vaccine Serum Free When Administered According to a Simulated Rabies Post Exposure Regimen in Healthy Adults Completed NCT03145766 Phase 2
43 A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects Completed NCT00656097 Phase 2
44 Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Rabies Human Diploid Cell Vaccine (Imovax® Rabies) Administered in a Simulated Rabies Post-exposure Regimen in Healthy Adults Completed NCT01877395 Phase 2
45 Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen Completed NCT02956421 Phase 2
46 A Three-Year Clinical Study on Immunogenicity, Safety and Booster Response of Purified Chick Embryo Cell Rabies Vaccine (Pcecv) Administered Intramuscularly or Intradermally to 12- to 18-Month-Old Thai Children Concomitantly With Japanese Encephalitis Vaccine Completed NCT00703521 Phase 2
47 Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults Completed NCT00948272 Phase 2
48 A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects Completed NCT01228383 Phase 2
49 A Phase 2 Randomized Blinded Placebo Controlled Comparison of the Safety Pharmacokinetics and Pharmacodynamics of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines in Healthy Adult Subjects Completed NCT02956746 Phase 1, Phase 2
50 Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free (VRVg) in Comparison With the Human Diploid Cell Vaccine, Imovax® Rabies in a Pre-exposure Prophylaxis Regimen in Healthy Children and Adolescents Aged 2 to 17 Years Completed NCT01930357 Phase 2

Search NIH Clinical Center for Rabies

Cochrane evidence based reviews: rabies

Genetic Tests for Rabies

Anatomical Context for Rabies

MalaCards organs/tissues related to Rabies:

40
Brain, Testes, Kidney, Cortex, Spinal Cord, T Cells, Skin

Publications for Rabies

Articles related to Rabies:

(show top 50) (show all 13461)
# Title Authors PMID Year
1
Cholesterol 25-hydroxylase suppresses rabies virus infection by inhibiting viral entry. 61 42
31552533 2019
2
Progress towards rabies control and elimination in Vietnam. 61 42
31564730 2019
3
Animal bite injuries in the accident and emergency unit at Mulago Hospital in Kampala, Uganda. 61 42
31489090 2019
4
Modulation of HLA-G and HLA-E expression in human neuronal cells after rabies virus or herpes virus simplex type 1 infections. 54 61
17400066 2007
5
Immunohistochemical evaluation of mx protein expression in canine encephalitides. 54 61
17099155 2006
6
Expression of the interferon-alpha/beta-inducible bovine Mx1 dynamin interferes with replication of rabies virus. 54 61
16202617 2006
7
Modulation of HLA-G expression in human neural cells after neurotropic viral infections. 54 61
16306594 2005
8
High level of Bcl-2 counteracts apoptosis mediated by a live rabies virus vaccine strain and induces long-term infection. 54 61
14554083 2003
9
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. 54 61
12660934 2003
10
B-cell responses to myelin basic protein and its epitopes in autoimmune encephalomyelitis induced by Semple rabies vaccine. 54 61
10430042 1999
11
Antibodies to human myelin proteins and gangliosides in patients with acute neuroparalytic accidents induced by brain-derived rabies vaccine. 54 61
9846820 1998
12
Molecular mimicry between the rabies virus glycoprotein and human immunodeficiency virus-1 GP120: cross-reacting antibodies induced by rabies vaccination. 54 61
9345046 1997
13
Clonal analysis of a human antibody response. II. Sequences of the VH genes of human IgM, IgG, and IgA to rabies virus reveal preferential utilization of VHIII segments and somatic hypermutation. 54 61
8432980 1993
14
Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies. 54 61
2058261 1991
15
Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. 54 61
2153188 1990
16
Novel strategy for expression and characterization of rabies virus glycoprotein. 61
31904423 2020
17
Increased detection of rabies virus in bats in Ceará State (Northeast Brazil) after implementation of a passive surveillance programme. 61
31797575 2020
18
Faeces as a novel material to estimate lyssavirus prevalence in bat populations. 61
31814288 2020
19
A survey investigating the current practice of French health professionals regarding infection risk after monkey bites. 61
31828958 2020
20
Rabies virus and Histoplasma suramericanum coinfection in a bat from southeastern Brazil. 61
31750629 2020
21
Seroconversion after three doses of intramuscular rabies vaccine as a post-exposure treatment. 61
31981771 2020
22
The Serological Prevalence of Rabies Virus-Neutralizing Antibodies in the Bat Population on the Caribbean Island of Trinidad. 61
32033370 2020
23
Public Veterinary Medicine: Public Health Rabies virus variants identified in Nuevo Leon State, Mexico, from 2008 to 2015. 61
31999515 2020
24
Barrel cortex VIP/ChAT interneurons suppress sensory responses in vivo. 61
32027647 2020
25
Livestock owners' anthrax prevention practices and its associated factors in Sekota Zuria district, Northeast Ethiopia. 61
32013973 2020
26
Next-generation serology: integrating cross-sectional and capture-recapture approaches to infer disease dynamics. 61
31655002 2020
27
Multivariate analysis of the immune response to different rabies vaccines. 61
31855742 2020
28
Update from the Advisory Committee on Immunization Practices. 61
32016424 2020
29
Human Rabies - Utah, 2018. 61
32027626 2020
30
Imaging Features in Rabies Encephalities. 61
32009369 2020
31
Antiviral Ranpirnase TMR-001 Inhibits Rabies Virus Release and Cell-to-Cell Infection In Vitro. 61
32033253 2020
32
Immune responses in mice and pigs after oral vaccination with rabies virus vectored Nipah disease vaccines. 61
31928698 2020
33
Comprehensive analysis of the ubiquitome in rabies virus-infected brain tissue of Mus musculus. 61
31928699 2020
34
Rabies knowledge and practices among human and veterinary health workers in Chad. 61
31542375 2020
35
Structural Analysis of Rabies Virus Glycoprotein Reveals pH-Dependent Conformational Changes and Interactions with a Neutralizing Antibody. 61
32004500 2020
36
A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody. 61
31971485 2020
37
Population- and Variant-Based Genome Analyses of Viruses from Vaccine-Derived Rabies Cases Demonstrate Product Specific Clusters and Unique Patterns. 61
31963517 2020
38
Assessment of knowledge, attitude and practice towards rabies and associated factors among household heads in Mekelle city, Ethiopia. 61
31937297 2020
39
Factors influencing the immune response after a double-dose 2-visit pre-exposure rabies intradermal vaccination schedule: A retrospective study. 61
31931134 2020
40
Intradermal rabies pre-exposure vaccination schedules in older travellers: comparison of immunogenicity post-primary course and post-booster. 61
31943042 2020
41
Implementation of a mass canine rabies vaccination campaign in both rural and urban regions in southern Malawi. 61
31971943 2020
42
Rabies Outbreak in Captive Big Brown Bats (Eptesicus fuscus) Used in a White-Nose Syndrome Vaccine Trial. 61
31295082 2020
43
SAFETY, IMMUNOGENICITY, AND EFFICACY OF INTRAMUSCULAR AND ORAL DELIVERY OF ERA-G333 RECOMBINANT RABIES VIRUS VACCINE TO BIG BROWN BATS (EPTESICUS FUSCUS). 61
31895645 2020
44
The common vampire bat Desmodus rotundus (Chiroptera: Phyllostomidae) and the transmission of the rabies virus to livestock: A contact network approach and recommendations for surveillance and control. 61
31756671 2020
45
Sequence analysis of nucleoprotein gene reveals the co-circulation of lineages and sublineages of rabies virus in herbivorous in Rio Grande do Sul state, Brazil. 61
31953649 2020
46
Comparison of Reverse Transcription Loop-Mediated Isothermal Amplification Method with SYBR Green Real-Time RT-PCR and Direct Fluorescent Antibody Test for Diagnosis of Rabies. 61
31474697 2020
47
Using the LN34 Pan-Lyssavirus Real-Time RT-PCR Assay for Rabies Diagnosis and Rapid Genetic Typing from Formalin-Fixed Human Brain Tissue. 61
31963651 2020
48
One-week, two-visit, double-dose, intra-dermal (22ID) rabies vaccination schedule for travelers: Time/dose sparing, effective but "off label". 61
31982631 2020
49
Targeting Small Molecule Delivery to the Brain and Spinal Cord via Intranasal Administration of Rabies Virus Glycoprotein (RVG29)-Modified PLGA Nanoparticles. 61
31991664 2020
50
CHALLENGES AND OPPORTUNITIES FOR WILDLIFE DISEASE SURVEILLANCE IN SRI LANKA. 61
31917632 2020

Variations for Rabies

Expression for Rabies

Search GEO for disease gene expression data for Rabies.

Pathways for Rabies

Pathways related to Rabies according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TLR3 STAT2 STAT1 PTPN4 PML NCAM1
2
Show member pathways
13.25 TLR3 STAT2 STAT1 NGFR CXCL10 CD40LG
3
Show member pathways
13.17 STAT2 STAT1 PML NCAM1 MX1 IRF7
4
Show member pathways
13.04 TLR3 STAT2 STAT1 MX1 IRF7 IRF3
5
Show member pathways
12.85 TLR3 STAT2 STAT1 NGFR MX1 IRF3
6
Show member pathways
12.8 TLR3 STAT2 STAT1 IRF7 IRF3 CCL5
7
Show member pathways
12.72 STAT2 STAT1 HSPA4 CXCL10 CCL5
8
Show member pathways
12.69 TLR3 IRF7 IRF3 DHX58 DDX58 CXCL10
9 12.66 TLR3 STAT2 STAT1 PML IRF7 IRF3
10
Show member pathways
12.56 TLR3 STAT2 STAT1 PML MX1 IRF7
11
Show member pathways
12.35 STAT2 STAT1 PML NCAM1 MX1 IRF7
12
Show member pathways
12.26 TLR3 IRF7 IRF3 DDX58
13
Show member pathways
12.19 STAT2 STAT1 PML NGFR MX1 IRF7
14 12.15 STAT2 STAT1 IRF7 IRF3 CCL5
15 11.88 TLR3 STAT2 STAT1 NCAM1 IRF7 IRF3
16 11.25 STAT2 STAT1 CXCL10
17
Show member pathways
10.79 STAT2 STAT1 MX1 IRF7 IRF3 DDX58

GO Terms for Rabies

Cellular components related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 TLR3 STAT2 STAT1 PTPN4 PML OCA2

Biological processes related to Rabies according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TLR3 STAT2 STAT1 IRF7 IRF3 DDX58
2 immune system process GO:0002376 10.05 TLR3 PML MX1 IRF7 IRF3 DHX58
3 innate immune response GO:0045087 10.02 TLR3 PML MX1 IRF7 IRF3 DHX58
4 cytokine-mediated signaling pathway GO:0019221 9.92 STAT2 STAT1 CXCL10 CCL5
5 defense response GO:0006952 9.85 TLR3 STAT2 STAT1 MX1 CXCL10
6 viral process GO:0016032 9.81 STAT2 STAT1 PML NCAM1 IRF7 IRF3
7 cellular response to interferon-gamma GO:0071346 9.79 TLR3 STAT1 CCL5
8 response to cytokine GO:0034097 9.77 STAT1 PML CCL5
9 interferon-gamma-mediated signaling pathway GO:0060333 9.77 STAT1 PML NCAM1 IRF7 IRF3
10 response to exogenous dsRNA GO:0043330 9.74 TLR3 IRF3 DDX58
11 positive regulation of type I interferon production GO:0032481 9.73 TLR3 IRF7 IRF3 DHX58
12 negative regulation of type I interferon production GO:0032480 9.72 IRF3 DHX58 DDX58
13 type I interferon signaling pathway GO:0060337 9.72 STAT2 STAT1 MX1 IRF7 IRF3
14 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.71 TLR3 IRF7 IRF3
15 positive regulation of interferon-beta production GO:0032728 9.71 TLR3 IRF7 IRF3 DDX58
16 cellular response to exogenous dsRNA GO:0071360 9.67 TLR3 IRF3 DDX58
17 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.61 IRF7 IRF3
18 regulation of type I interferon production GO:0032479 9.61 IRF7 IRF3
19 negative regulation of macrophage apoptotic process GO:2000110 9.58 IRF7 CCL5
20 detection of virus GO:0009597 9.58 TLR3 DDX58
21 MDA-5 signaling pathway GO:0039530 9.56 IRF7 IRF3
22 positive regulation of interferon-alpha production GO:0032727 9.56 STAT1 IRF7 IRF3 DDX58
23 type I interferon biosynthetic process GO:0045351 9.52 IRF7 IRF3
24 response to virus GO:0009615 9.5 TLR3 MX1 IRF7 DHX58 DDX58 CXCL10
25 defense response to virus GO:0051607 9.32 TLR3 STAT2 STAT1 PML MX1 IRF7

Molecular functions related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 TLR3 STAT2 STAT1 PTPN4 PML OCA2
2 identical protein binding GO:0042802 9.56 TLR3 STAT2 STAT1 MX1 IRF3 DDX58
3 double-stranded RNA binding GO:0003725 9.43 TLR3 DHX58 DDX58
4 CCR5 chemokine receptor binding GO:0031730 9.16 STAT1 CCL5

Sources for Rabies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....